Payment overview · 2025
General Payments
$2,487.60
105 reported records · 27 companies
Healthcare provider profile · identity verified
Grace Tee, M.D
Allopathic & Osteopathic Physicians|Internal Medicine · SAN JOSE, CA · NPI 1689691461
Verified facts
What the public records show
CMS Open Payments records show Grace Tee, M.D received $2,487.60 in general payments during 2025 across 105 reported records.
Novo Nordisk Inc accounted for 15.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 40 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Kerendia, Linzess, Mounjaro, Ozempic, Paxlovid, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 205 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $378.57 | 15.2% | 14 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $202.27 | 8.1% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $196.91 | 7.9% | 9 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $194.75 | 7.8% | 9 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $154.57 | 6.2% | 8 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $149.87 | 6.0% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $138.53 | 5.6% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $137.93 | 5.5% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $104.66 | 4.2% | 4 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $97.09 | 3.9% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $93.10 | 3.7% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $92.15 | 3.7% | 4 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $88.90 | 3.6% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $66.45 | 2.7% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $54.19 | 2.2% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $44.60 | 1.8% | 2 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $43.00 | 1.7% | 2 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $34.43 | 1.4% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $31.08 | 1.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.67 | 1.1% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $26.71 | 1.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.89 | 1.0% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.88 | 1.0% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $20.16 | 0.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.90 | 0.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.57 | 0.8% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.77 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,487.60 | 105 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $293.73 | 11 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $293.73 | 11 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $154.57 | 8 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $149.87 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $145.49 | 7 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $143.18 | 7 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $138.53 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $138.27 | 7 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $104.66 | 4 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $97.09 | 5 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $88.90 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $84.84 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $82.43 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $79.81 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $70.02 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $68.55 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $68.55 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $66.45 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $64.00 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $55.61 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $54.19 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $53.01 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $44.60 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $43.60 | 3 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $43.00 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $40.10 | 2 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $34.43 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $28.67 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $26.71 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $26.17 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $25.88 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $25.88 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $25.78 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $24.55 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $22.13 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $20.16 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $20.16 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $19.90 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.57 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $17.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 91 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 30 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 94 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 56 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 205 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 25 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 31 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 49 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
56 | 27 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
30 | 13 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
94 | 27 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
91 | 37 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
49 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
94 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
205 | 42 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
31 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
91 | 37 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
25 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 898 | 261 |
| Losartan Potassium | Losartan Potassium | 677 | 209 |
| Amlodipine Besylate | Amlodipine Besylate | 639 | 208 |
| Famotidine | Famotidine | 393 | 152 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 317 | 108 |
| Fluticasone Propionate | Fluticasone Propionate | 289 | 99 |
| Levothyroxine Sodium | Levothyroxine Sodium | 286 | 72 |
| Metformin Hcl Er | Metformin Hcl | 271 | 79 |
| Metformin Hcl | Metformin Hcl | 270 | 79 |
| Metoprolol Succinate | Metoprolol Succinate | 259 | 79 |
| Gabapentin | Gabapentin | 256 | 84 |
| Ozempic | Semaglutide | 205 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 205 | 82 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 201 | 68 |
| Glipizide Er | Glipizide | 201 | 59 |
| Allopurinol | Allopurinol | 198 | 56 |
| Metoprolol Tartrate | Metoprolol Tartrate | 185 | 66 |
| Baclofen | Baclofen | 181 | 73 |
| Lisinopril | Lisinopril | 151 | 52 |
| Trazodone Hcl | Trazodone Hcl | 150 | 51 |
| Furosemide | Furosemide | 138 | 67 |
| Raloxifene Hcl | Raloxifene Hcl | 123 | 38 |
| Montelukast Sodium | Montelukast Sodium | 122 | 33 |
| Vascepa | Icosapent Ethyl | 118 | 28 |
| Tradjenta | Linagliptin | 108 | 37 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 104 | 34 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 101 | 51 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 99 | 89 |
| Buspirone Hcl | Buspirone Hcl | 99 | 28 |
| Lactulose | Lactulose | 98 | 69 |
| Jardiance | Empagliflozin | 94 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 93 | 55 |
| Eliquis | Apixaban | 91 | 37 |
| Alendronate Sodium | Alendronate Sodium | 90 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 89 | 36 |
| Meclizine Hcl | Meclizine Hcl | 89 | 46 |
| Pantoprazole Sodium | Pantoprazole Sodium | 89 | 43 |
| Simvastatin | Simvastatin | 85 | 23 |
| Atenolol | Atenolol | 77 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 77 | 37 |
| Icosapent Ethyl | Icosapent Ethyl | 77 | 27 |
| Hydralazine Hcl | Hydralazine Hcl | 74 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 74 | 21 |
| Cephalexin | Cephalexin | 73 | 67 |
| Doxazosin Mesylate | Doxazosin Mesylate | 70 | 21 |
| Carvedilol | Carvedilol | 68 | 29 |
| Finasteride | Finasteride | 68 | 21 |
| Tramadol Hcl | Tramadol Hcl | 64 | 32 |
| Ibuprofen | Ibuprofen | 62 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | 15 |
| Omeprazole | Omeprazole | 62 | 20 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 61 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 61 | 15 |
| Mirtazapine | Mirtazapine | 57 | 17 |
| Linzess | Linaclotide | 56 | 27 |
| Glimepiride | Glimepiride | 51 | 16 |
| Nystatin | Nystatin | 49 | 29 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 49 | 14 |
| Fenofibrate | Fenofibrate | 48 | 11 |
| Gemfibrozil | Gemfibrozil | 46 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 42 | 35 |
| Bupropion Hcl Sr | Bupropion Hcl | 41 | suppressed |
| Spironolactone | Spironolactone | 41 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 37 |
| Potassium Chloride | Potassium Chloride | 40 | 19 |
| Prednisone | Prednisone | 40 | 35 |
| Ventolin Hfa | Albuterol Sulfate | 40 | 13 |
| Clonazepam | Clonazepam | 39 | suppressed |
| Glipizide | Glipizide | 39 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 39 | 11 |
| Benazepril Hcl | Benazepril Hcl | 38 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 37 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 35 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 35 | 12 |
| Azithromycin | Azithromycin | 34 | 32 |
| Ezetimibe | Ezetimibe | 33 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 33 | 11 |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 32 | suppressed |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Rybelsus | Semaglutide | 31 | 17 |
| Sertraline Hcl | Sertraline Hcl | 31 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 30 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 30 | 13 |
| Promethazine Hcl | Promethazine Hcl | 30 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 30 | 12 |
| Valsartan | Valsartan | 29 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 27 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 25 | 25 |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Colchicine | Colchicine | 24 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 24 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | 15 |
| Lidocaine | Lidocaine | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | 14 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Kerendia | Finerenone | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 15 |
| Lovastatin | Lovastatin | 19 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 18 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Promethazine-Dm | Promethazine/Dextromethorphan | 17 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | 11 |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 14 | suppressed |
| Febuxostat | Febuxostat | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | 11 |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Alprazolam | Alprazolam | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Fluocinonide | Fluocinonide | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | 11 |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,487.60 · 105 records | Novo Nordisk Inc | AREXVY, AUSTEDO XR, Arikayce, BREZTRI, CAPLYTA, Dexcom G6 Transmitter, ELIQUIS, FANAPT, FARXIGA, FREESTYLE LIBRE 3, Fintepla, Fluad, Flucelvax, GVOKE HYPOPEN, JARDIANCE, KISUNLA, KRYSTEXXA, Kerendia, LINZESS, Leqembi, MOUNJARO, NURTEC ODT, NUZYRA, OTEZLA, Ozempic, PAXLOVID, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, VOQUEZNA, VRAYLAR, Vest Therapy Und, Wegovy, XHANCE, XIFAXAN, ZAVZPRET, ZENPEP, ZEPBOUND, ZORYVE | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error